AIA
PCRX icon

Avalon Investment & Advisory’s Pacira BioSciences PCRX Stock Holding History

Avalon Investment & Advisory’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-42,846
Closed -$2.28M – 324
2022
Q3 		$2.28M Sell
42,846
-2,832
-6% -$157K 0.07% 161
2022
Q2 		$2.66M Sell
45,678
-1,382
-3% -$90.5K 0.08% 153
2022
Q1 		$3.59M Buy
+47,060
New +$3.14M 0.09% 141

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Avalon Investment & Advisory's PCRX Position: Q4 2022 in Review

Avalon Investment & Advisory sold out of Pacira BioSciences (PCRX) in Q4 2022, closing a stake of 42,846 shares — an estimated $2.28M sold.

Avalon Investment & Advisory first reported a position in PCRX in Q1 2022 and held it in 3 quarters. The position peaked at $3.59M in Q1 2022. 273 funds tracked by Wall St. Rank hold PCRX as of Q4 2022.

  • Avalon Investment & Advisory reported no remaining Pacira BioSciences position as of Q4 2022 after selling out during the quarter.
  • Avalon Investment & Advisory sold 42,846 Pacira BioSciences shares in Q4 2022, an estimated $2.28M.
  • Avalon Investment & Advisory first reported a position in Pacira BioSciences in Q1 2022 and held it in 3 quarters.
  • Avalon Investment & Advisory's Pacira BioSciences position peaked at $3.59M in Q1 2022.
  • 273 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2022.

Based on Avalon Investment & Advisory's 13F filing for Q4 2022, filed 13 Feb 2023.